Skip to main content
Premium Trial:

Request an Annual Quote

Schering-Plough to Use MorphoSys HuCAL GOLD Technology

NEW YORK, May 17 (GenomeWeb News) - MorphoSys today said that Schering-Plough will use its HuCAL GOLD technology for two years. 

 

Terms of the deal, which can be extended for an additional three years, call for the drug maker to use the technology for drug-discovery programs at the firm's Palo Alto, Calif., research site. The contract also provides Schering-Plough with the option to develop HuCAL-derived therapeutic antibodies against up to 10 disease-related targets. 

 

In return, MorphoSys will receive an upfront payment, annual user fees, and optional R&D funding.

 

For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to receive license and milestone payments related to the successful advancement of projects in clinical development, and royalties on HuCAL antibodies developed under the agreement.

 

Further financial details were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.